The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Coffee and caffeine are speculated to be associated with the reduced risk of Parkinson’s disease (PD). The present study aimed to investigate the disease-modifying potential of caffeine on PD, either for healthy people or patients, through a meta-analysis. The electronic databases were searched using terms related to PD and coffee and caffeinated food products. Articles were included only upon fulfillment of clear diagnostic criteria for PD and details regarding their caffeine content. Reference lists of relevant articles were reviewed to identify eligible studies not shortlisted using these terms. In total, the present study enrolled 13 studies, nine were categorized into a healthy cohort and the rest into a PD cohort. The individuals in the healthy cohort with regular caffeine consumption had a significantly lower risk of PD during follow-up evaluation (hazard ratio (HR) = 0.797, 95% CI = 0.748–0.849, p < 0.001). The outcomes of disease progression in PD cohorts included dyskinesia, motor fluctuation, symptom onset, and levodopa initiation. Individuals consuming caffeine presented a significantly lower rate of PD progression (HR = 0.834, 95% CI = 0.707–0.984, p = 0.03). In conclusion, caffeine modified disease risk and progression in PD, among both healthy individuals or those with PD. Potential biological benefits, such as those obtained from adenosine 2A receptor antagonism, may require further investigation for designing new drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“that have been suggested to underlie the decrease in PD risk associated with coffee consumption [218,219].”
From Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis (2020) · cites this paper as [219]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 1×
“Caffeine is an adenosine A2A receptor antagonist [8].”
BackgroundLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821 · cited 1×
“However, responses to one-night washout are variable, and the effect of levodopa may last for 2 weeks [43].”
BackgroundEpidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199 · cited 1×
“Risk factors for PD include genetic mutations, environmental toxins, and lifestyle [1].”
BackgroundA Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901 · cited 1×
“Moreover, if the intervention itself causes certain symptomatic effects in conjunction, similar to rasagiline or caffeine, it would be challenging to distinguish between disease modification and symptomatic effect [44].”
BackgroundPramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“[17] USA Health Professionals’ Follow-Up Study and Nurses’ Health Study (1976 and 1986/1994) 135,916 Semiquantitative food-frequency questionnaire (SFFQ) Caffeine was 137 mg per cup of coffee, 47 mg per cup of tea, 46 mg per can or bottle of cola beverage, and 7 mg per serving of chocolate candy.”
BackgroundNeuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Genetics of caffeine consumption and responses to caffeine
Yang, A., Palmer, A. A., & de Wit, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1900-1 · Cited by 309 · cited 1×
“Moreover, genetic polymorphism, sex, and heterogeneity in caffeine metabolism also influence the effects of caffeine [20,40,41].”
BackgroundArendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
The neuroprotective effects of caffeine in neurodegenerative diseases
Kolahdouzan, M., & Hamadeh, M. J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12684 · Cited by 302 · cited 1×
“The neuroprotective effects of caffeine involved the antagonism of the adenosine A2A receptor, down-regulating the down streaming phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway, and avoiding excessive calcium releasing-related neurotoxicity and neuroinflammation [10], which has been expe…”
BackgroundCaffeine for treatment of Parkinson disease: A randomized controlled trial
Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Rios Romenets, S., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 298 · cited 2×
“[19] US Nurses’ Health Study (1976/1998) 121,700 women semiquantitative food-frequency questionnaire (SFFQ) caffeine was 137 mg per cup of coffee, 47 mg per cup of tea, 46 mg per can or bottle of cola beverage, and 7 mg per serving of chocolate candy.”
BackgroundRajput, A. H. (2014) · Movement Disorders · doi:10.1002/mds.25800 · Cited by 290
Coffee and tea consumption and the risk of Parkinson's disease
Hu, G., Bidel, S., Jousilahti, P., Antikainen, R., & Tuomilehto, J. (2007) · Movement Disorders · doi:10.1002/mds.21706 · Cited by 280 · cited 1×
“[23] IL 278 Onset of PD motor symptoms Interview the number of cups of coffee per day 10.”
BackgroundCaffeine as a Protective Factor in Dementia and Alzheimer's Disease
Eskelinen, M. H., & Kivipelto, M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1404 · Cited by 259 · cited 1×
“In a similar manner, the protective effect of coffee was also noted in dementia and AD [6], whereby caffeine reversed the cognitive impairment and decreased the amyloid burden in transgenic AD mice model [7].”
BackgroundAntiparkinsonian effect of a new selective adenosine A2Areceptor antagonist in MPTP-treated monkeys
Grondin, R., Bédard, P. J., Tahar, A. H., Grégoire, L., Mori, A., & Kase, H. (1999) · Neurology · doi:10.1212/wnl.52.8.1673 · Cited by 249
Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease
Ascherio, A., Chen, H., Schwarzschild, M. A., Zhang, S. M., Colditz, G. A., & Speizer, F. E. (2003) · Neurology · doi:10.1212/01.wnl.0000046523.05125.87 · Cited by 234 · cited 1×
“[22] US CPS II–Nutrition cohort (1992/2007) 184,190 Food Frequency Questionnaire 137 and 47 mg per cup of coffee and tea, respectively, 46 mg per can or bottle of cola; and 7 mg per serving of chocolate.”
BackgroundProspective Study of Cigarette Smoking and the Risk of Developing Idiopathic Parkinson's Disease
Grandinetti, A., Morens, D. M., Reed, D., & MacEachern, D. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116960 · Cited by 220 · cited 1×
“[21] SG Singapore Chinese Health Study (1993/2005) 63,257 a validated, semiquantitative food frequency section questionnaire Singapore Food Composition Table, a food-nutrient database that lists the levels of 96 nutritive/nonnutritive components (including caffeine) per 100 g of cooked food and beverages Interview and…”
BackgroundVingerhoets, F. J. G., Snow, B. J., Lee, C. S., Schulzer, M., Mak, E., & Calne, D. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360512 · Cited by 218 · cited 1×
“Considering that steady neurodegeneration in PD precedes the onset of motor symptoms for decades and persists thereafter [30], caffeine was speculated to have disease-modifying potential throughout the course of the disease in this study.”
BackgroundBibbiani, F., Oh, J. D., Petzer, J. P., Castagnoli, N., Chen, J.-F., Schwarzschild, M. A., & Chase, T. N. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00250-4 · Cited by 204
Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders
Pinares-Garcia, P., Stratikopoulos, M., Zagato, A., Loke, H., & Lee, J. (2018) · Brain Sciences · doi:10.3390/brainsci8080154 · Cited by 200
Parkinson's disease: Evidence for environmental risk factors
Kieburtz, K., & Wunderle, K. B. (2013) · Movement Disorders · doi:10.1002/mds.25150 · Cited by 199 · cited 1×
“An epidemiological study reported some protective factors for PD worldwide, such as female sex, physical activity, and smoking [2].”
BackgroundA further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
Ambrosi, G., Cerri, S., & Blandini, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1149-z · Cited by 195 · cited 1×
“Excessive intracellular calcium and glutamate levels are responsible for excitotoxicity in neurodegenerative diseases, including PD [34].”
BackgroundHellenbrand, W., Boeing, H., Robra, B.-P., Seidler, A., Vieregge, P., Nischan, P., Joerg, J., Oertel, W. H., Schneider, E., & Ulm, G. (1996) · Neurology · doi:10.1212/wnl.47.3.644 · Cited by 195 · cited 1×
“Patients with PD are less frequent habitual consumers of caffeinated food [3,4].”
BackgroundTan, E.-K., Tan, C., Fook-Chong, S. M. C., Lum, S. Y., Chai, A., Chung, H., Shen, H., Zhao, Y., Teoh, M. L., Yih, Y., et al. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.07.006 · Cited by 186 · cited 1×
“The consumption of either tea or coffee exhibited similar effects on the reduction of the risk of PD [5].”
BackgroundCaffeine and risk of Parkinson’s disease in a large cohort of men and women
Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S., & Ascherio, A. (2012) · Movement Disorders · doi:10.1002/mds.25076 · Cited by 185 · cited 1×
“[25] GB 183 Newly diagnosed Verbal interview about the average level of exposure before baseline Cups of tea: 47 mg caffeine Cup of coffee: 62 mg caffeine 59 months 1.”
BackgroundTan, L. C., Koh, W.-P., Yuan, J.-M., Wang, R., Au, W.-L., Tan, J. H., Tan, E.-K., & Yu, M. C. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm338 · Cited by 183 · cited 1×
“[24] US 228 Early PD questionnaire assessing both current (“in the past week”) and prior (“on average over the past 5 years”) caffeine intake Coffee (85 mg caffeine/5 oz) Tea (36 mg caffeine/5 oz) Soda (45 mg caffeine/12 oz) 5.”
BackgroundProspective study of coffee consumption and risk of Parkinson’s disease
Sääksjärvi, K., Knekt, P., Rissanen, H., Laaksonen, M. A., Reunanen, A., & Männistö, S. (2008) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602788 · Cited by 182 · cited 1×
“[15] US NIH-AARP Diet and Health Study (1995/2010) 566,401 Diet History Questionnaire nutrient calculation: 1994–1996 US Department of Agriculture’s Continuing Survey of Food Intakes by Individuals.”
BackgroundWei, C. J., Li, W., & Chen, J. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.018 · Cited by 182 · cited 1×
“In the central nervous system, the adenosine A2A receptor is exclusively expressed in dopaminergic neurons, and the activation of the adenosine A2A receptor triggers the cAMP-protein kinase A-dependent elevation of intracellular calcium and release of glutamate [33].”
BackgroundCaffeine Intake, Smoking, and Risk of Parkinson Disease in Men and Women
Liu, R., Guo, X., Park, Y., Huang, X., Sinha, R., Freedman, N. D., Hollenbeck, A. R., Blair, A., & Chen, H. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr451 · Cited by 170 · cited 1×
“Grandinetti et al [18] US Honolulu Heart Program-Japanese and Okinawan ancestry (1965/1991) 8006 men Questionnaires NA Medical records”
BackgroundRisk and protective factors for Parkinson's disease: A study in Swedish twins
Wirdefeldt, K., Gatz, M., Pawitan, Y., & Pedersen, N. L. (2005) · Annals of Neurology · doi:10.1002/ana.20307 · Cited by 135 · cited 1×
“[16] SE Swedish Twin Registry (1961 and 1973/without clear mentioning) 52,149 Questionnaires Did not provide the formula Inpatient Discharge Register and Cause of Death Register”
BackgroundHuman Adenosine A2A Receptor: Molecular Mechanism of Ligand Binding and Activation
Carpenter, B., & Lebon, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00898 · Cited by 127
New treatments for levodopa‐induced motor complications
Rascol, O., Perez‐Lloret, S., & Ferreira, J. J. (2015) · Movement Disorders · doi:10.1002/mds.26362 · Cited by 113 · cited 1×
“Istradefylline, an FDA-approved adenosine A2A receptor antagonist currently used for treating PD, reduces off time and improves the motor symptoms of patients with PD albeit with complications including the exacerbation of dyskinesia [36].”
BackgroundSmoking and tea consumption delay onset of Parkinson's disease
Kandinov, B., Giladi, N., & Korczyn, A. D. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.02.011 · Cited by 110 · cited 1×
“[26] IL 79 de novo, drug naïve Caffeine Consumption Questionnaire i.”
BackgroundHealth benefits of methylxanthines in neurodegenerative diseases
Oñatibia‐Astibia, A., Franco, R., & Martínez‐Pinilla, E. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600670 · Cited by 105 · cited 1×
“The effect of some promising ingredients in coffee, such as eicosanoyl-5-hydroxytryptamide [31] or methylxanthine [50] had not been investigated in the present study due to the lack of standard assessment, such as the dietary questionnaires for the amount of daily intake.”
BackgroundDeterminants of delayed diagnosis in Parkinson’s disease
Breen, D. P., Evans, J., Farrell, K., Brayne, C., & Barker, R. A. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6905-3 · Cited by 104 · cited 1×
“Most individuals with PD were either misdiagnosed or underwent unnecessary treatment years before reaching a final diagnosis [42].”
BackgroundJiméanez‐Jiméanez, F. J., Mateo, D., & Giméanez‐Roldan, S. (1992) · Movement Disorders · doi:10.1002/mds.870070407 · Cited by 102 · cited 1×
“Patients with PD are less frequent habitual consumers of caffeinated food [3,4].”
BackgroundSerum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Fujimaki, M., Saiki, S., Li, Y., Kaga, N., Taka, H., Hatano, T., Ishikawa, K.-I., Oji, Y., Mori, A., Okuzumi, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004888 · Cited by 100
Arab, L., Biggs, M. L., O'Meara, E. S., Longstreth, W. T., Crane, P. K., & Fitzpatrick, A. L. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110431 · Cited by 98 · cited 1×
“Moreover, genetic polymorphism, sex, and heterogeneity in caffeine metabolism also influence the effects of caffeine [20,40,41].”
BackgroundPredictors of motor complications in early Parkinson's disease: A prospective cohort study
Kelly, M. J., Lawton, M., Baig, F., Ruffmann, C., Barber, T. R., Lo, C., Klein, J. C., Ben‐Shlomo, Y., & Hu, M. T. (2019) · Movement Disorders · doi:10.1002/mds.27783 · Cited by 90 · cited 1×
“Nevertheless, the degeneration of dopaminergic neurons is not the only underlying factor [45].”
BackgroundYan, R., Zhang, J., Park, H.-J., Park, E. S., Oh, S., Zheng, H., Junn, E., Voronkov, M., Stock, J. B., & Mouradian, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813365115 · Cited by 88 · cited 2×
“The effect of some promising ingredients in coffee, such as eicosanoyl-5-hydroxytryptamide [31] or methylxanthine [50] had not been investigated in the present study due to the lack of standard assessment, such as the dietary questionnaires for the amount of daily intake.”
BackgroundResultMotor complications in an incident Parkinson's disease cohort
Scott, N. W., Macleod, A. D., & Counsell, C. E. (2016) · European Journal of Neurology · doi:10.1111/ene.12751 · Cited by 69 · cited 2×
“[28] GB 183 Newly diagnosed Verbal interview about the average level of exposure before baseline Cups of tea: 47 mg caffeine Cup of coffee: 62 mg caffeine 59 months 1.”
BackgroundMachado-Filho, J. A., Correia, A. O., Montenegro, A. B. A., Nobre, M. E. P., Cerqueira, G. S., Neves, K. R. T., Naffah‐Mazzacoratti, M. D. G., Cavalheiro, É. A., Brito, G. A. D. C., & Viana, G. S. D. B. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.01.051 · Cited by 69 · cited 1×
“The adenosine A2A receptor is also involved in neuroinflammation-mediated neuronal dysfunction and degeneration [35].”
BackgroundCaffeine consumption and risk of dyskinesia in CALM‐PD
Wills, A. A., Eberly, S., Tennis, M., Lang, A. E., Messing, S., Togasaki, D., Tanner, C. M., Kamp, C., Chen, J., Oakes, D., et al. (2013) · Movement Disorders · doi:10.1002/mds.25319 · Cited by 58
A Meta-Analysis of Tea Drinking and Risk of Parkinson's Disease
Li, F.-J., Ji, H.-F., & Shen, L. (2012) · The Scientific World Journal · doi:10.1100/2012/923464 · Cited by 57 · cited 1×
“Although another component in coffee, that is, eicosanoyl-5-hydroxytryptamide, is believed to protect against neurodegeneration [31], a similar association found for tea consumption further corroborated the finding that caffeine is the key protective agent in coffee [32].”
ResultGene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2
Chuang, Y.-H., Lill, C. M., Lee, P.-C., Hansen, J., Lassen, C. F., Bertram, L., Greene, N., Sinsheimer, J. S., & Ritz, B. (2016) · Neuroepidemiology · doi:10.1159/000450855 · Cited by 48
Onset and progression factors in Parkinson’s disease: A systematic review
Martino, R., Candundo, H., Lieshout, P. H. H. M. V., Shin, S., Crispo, J. A. G., & Barakat, C. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.04.003 · Cited by 46 · cited 1×
“Third, instead of coffee or caffeine, some factors are known to affect the risk of PD, such as diabetes, pesticide exposure and the well-water drinking [51].”
BackgroundHow to optimize the treatment of early stage Parkinson’s disease
Stocchi, F., Vacca, L., & Radicati, F. G. (2015) · Translational Neurodegeneration · doi:10.1186/2047-9158-4-4 · Cited by 38 · cited 1×
“considered the initiation of levodopa treatment as a marker for disease progression, which was highly influenced by the subjective and objective conditions of patients with PD [49].”
BackgroundKelsey, J. E., Langelier, N. A., Oriel, B. S., & Reedy, C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1319-0 · Cited by 37 · cited 1×
“[13] SE Swedish Twin Registry (1961 and 1973/without clear mentioning) 52,149 questionnaires Did not provide the formula Inpatient Discharge Register and Cause of Death Register”
BackgroundGołembiowska, K., Wardas, J., Noworyta-Sokołowska, K., Kamińska, K., & Górska, A. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9372-1 · Cited by 36
Bové, J., Serrats, J., Mengod, G., Cortés, R., TOLOSA, E. S., & Marín, C. (2005) · Experimental Brain Research · doi:10.1007/s00221-005-2302-1 · Cited by 35 · cited 1×
“[12] FIN Finnish Mobile Clinic Health Examination Survey (1973/1994) 7246 self-administered, health questionnaire Cups of coffee National Social Insurance Institution’s Register”
MethodCaffeine consumption and the 4-year progression of de novo Parkinson's disease
Moccia, M., Erro, R., Picillo, M., Vitale, C., Longo, K., Amboni, M., Pellecchia, M. T., & Barone, P. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.005 · Cited by 34 · cited 1×
“[29] IL 79 de novo, drug naïve Caffeine Consumption Questionnaire i.”
BackgroundCaffeine, creatine, GRIN2A and Parkinson's disease progression
Simon, D. K., Wu, C., Tilley, B. C., Lohmann, K., Klein, C., Payami, H., Wills, A.-M. A., Aminoff, M. J., Bainbridge, J. L., Dewey, R. B., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.02.032 · Cited by 32
Kim, I. Y., O'Reilly, É. J., Hughes, K. C., Gao, X., Schwarzschild, M. A., McCullough, M. L., Hannan, M. T., Betensky, R. A., & Ascherio, A. (2018) · Movement Disorders · doi:10.1002/mds.27279 · Cited by 24
Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat
Reyhani‐Rad, S., & Mahmoudi, J. (2016) · Acta Cirúrgica Brasileira · doi:10.1590/s0102-865020160020000008 · Cited by 18 · cited 1×
“[14] US Health Professionals’ Follow-Up Study and Nurses’ Health Study (1976 and 1986/1994) 135,916 semiquantitative food-frequency questionnaire (SFFQ) caffeine was 137 mg per cup of coffee, 47 mg per cup of tea, 46 mg per can or bottle of cola beverage, and 7 mg per serving of chocolate candy.”
BackgroundWu, T. L., Wang, C., Lin, F. J., & Wu, R. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.11.049 · Cited by 1
Cited by
Ikram, M. A., Park, T. J., Ali, T., & Kim, M. O. (2020) · Antioxidants · doi:10.3390/antiox9090902 · Cited by 170
Schiess, N., Cataldi, R., Okun, M. S., Fothergill‐Misbah, N., Dorsey, E. R., Bloem, B. R., Barretto, M., Bhidayasiri, R., Brown, R. J., Chishimba, L., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1783 · Cited by 158
Caffeine and Its Antioxidant Properties—It Is All about Dose and Source
Ősz, B.-E., Jîtcă, G., Ștefănescu, R., Puşcaş, A., Tero-Vescan, A., & Vari, C.-E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113074 · Cited by 177
Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis
Iriondo-DeHond, A., Uranga, J. A., del Castillo, M. D., & Abalo, R. (2020) · Nutrients · doi:10.3390/nu13010088 · Cited by 126
“As mentioned for caffeine, CA and CGA are coffee components with antioxidant properties and neuroprotective effects against dopaminergic neurotoxicity [216,217] that have been suggested to underlie the decrease in PD risk associated with coffee consumption [218,219].”
BackgroundThe Role of Diet and Dietary Patterns in Parkinson’s Disease
Knight, E., Geetha, T., Burnett, D. O., & Babu, J. R. (2022) · Nutrients · doi:10.3390/nu14214472 · Cited by 111
“A metaanalysis observed that caffeine consumption typically from coffee is inversely related to PD risk and progression [51].”
Background
Metadata
- Authors
- Hong, C. T., Chan, L., & Bai, C.-H.
- Affiliations
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University Hospital (TW)
- Corresponding author
- Chan, Lung
- Bai, Chyi-Huey
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-06-22
- Volume
- 12
- Issue
- 6
- Pages
- 1860
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC7353179
- OpenAlex
- W3036886081
- Cited by
- 113
- References
- 57
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 29 · 2023: 17 · 2022: 18 · 2021: 18 · 2020: 6
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-06-22)
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- caffeine, Parkinson's disease, coffee consumption, disease risk, disease progression, dyskinesia, motor fluctuations, neuroprotection
- MeSH terms
- Caffeine, Coffee, Humans, Levodopa, Parkinson Disease, Cohort Studies, Proportional Hazards Models, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.